Tezspire Shows Strong Phase 3 Results in EoE, Positioning as First Major Dupixent Challenger

Amgen and AstraZeneca’s Tezspire showed high histologic remission and symptom improvement in Phase 3 EoE trial, positioning it as a potential Dupixent rival.